Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. BRIEF-Innate Pharma and Sanofi collaborate on antibody-drug conjugates

    Headlines

    Thu, 16 Apr 2015

    * Innate Pharma and Sanofi SA collaborate on next generation antibody-drug conjugates

  2. Sanofi to launch Toujeo diabetes drug in U.S. on Monday -source

    Headlines

    Fri, 27 Mar 2015

    PARIS, March 27 (Reuters) - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter.

  3. UPDATE 1- Sanofi test shows lixisenatide doesn't increase cardiovascular risk

    Headlines

    Thu, 19 Mar 2015

    PARIS, March 19 (Reuters) - Sanofi 's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday.

  4. Sanofi says test shows lixisenatide doesn't increase cardiovascular risk

    Headlines

    Thu, 19 Mar 2015

    PARIS, March 19 (Reuters) - Drugmaker Sanofi said its lixisenatide drug for the treatment of type 2 diabetes did not increase cardiovascular risk among high risk patients in a study it conducted.

  5. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

    Headlines

    Tue, 17 Mar 2015

    Medium 8 4 Unilever UL* 2 Wide 42.06 1.11 3.5 Medium 9 4 McDonald's MCD 3 Wide 96.35 0.98 3.4 Medium 5 1 Sanofi SNY * 4 Wide 47.07 0.86 3.4 Medium 6 2 EmersonElec EMR 4 Wide 55.26 0.8 3.3 Medium 7 1 ExxonMobil XOM 4 Wide 83

  6. Sanofi's Appointment of Brandicourt Replaces a Key Uncertainty With a Strong Leader

    Commentary

    Thu, 19 Feb 2015

    Sanofi announced the appointment ..... s ousting of previous CEO Chris Viehbacher in late 2014. While the appointment ..... industry experience should guide Sanofi well through several new product ..... products will be needed as Sanofi prepares to launch several

  7. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Video Reports

    Fri, 2 Jan 2015

    year's ranking, the top two firms were [TICKER: SNY ] Sanofi ( SNY ) and Merck (MRK). And just taking those one at ..... incident rate cancers like lung cancer. [TICKER: SNY ] Sanofi is a firm where the pipeline is not as strong as Merck

    SNY Sanofi found at 1:30, 2:12, 3:51

    ranking and why? Conover: In this year's ranking, the top two firms were [TICKER: SNY ] Sanofi SNY and Merck (MRK). And just taking those one at a time: Merck's a firm that is really in this transitionary period of
    shift in how we treat very large incident rate cancers like lung cancer. [TICKER: SNY ] Sanofi is a firm where the pipeline is not as strong as Merck, but it's a firm that doesn't have a lot of
    having me. Coffina: In conclusion, in this year's Big Pharma ranking, Merck and [TICKER: SNY ] Sanofi came out on top--Merck because of its very strong pipeline and [TICKER: SNY ] Sanofi mostly because of its lack of patent losses over the next five years. On the other end of the spectrum, Pfizer and [TICKER:GSK]
  8. 5 Wide-Moat Stocks That Were Left Behind in 2014

    Video Reports

    Fri, 2 Jan 2015

    care stock did well, including wide-moat [TICKER: SNY ] Sanofi . Glaser: Health-care stocks looked very strong in 2014, driven partially by an M&A boom. But [TICKER: SNY ] Sanofi looked a lot weaker, and there are a few things happening

    SNY Sanofi found at 5:02, 6:07

    health care in 2014, but not every health-care stock did well, including wide-moat [TICKER: SNY ] Sanofi . Glaser: Health-care stocks looked very strong in 2014, driven partially by an M&A boom. But [TICKER: SNY ] Sanofi looked a lot weaker, and there are a few things happening here. One were fundamental concerns about the business. Questions about what's
    able to actually reap those cash flows. We saw this stewardship hiccup at [TICKER: SNY ] Sanofi , and investors weren't happy about that. I think this highlights the importance of making sure that strong stewardship is there instead of
  9. Health Care: A Strong Run, but Some Stocks Still Look Undervalued

    Headlines

    Wed, 31 Dec 2014

    Wide Medium SEK 65.50 Sanofi $59 Wide Medium $41 ..... positioned for growth. Sanofi SNY Despite some weakness in ..... insulin drugs, we expect Sanofi 's key narrow- and wide ..... community underappreciates Sanofi 's strong competitive advantages

  10. From Barron’s, December 1, 2014 (Part 1)

    Commentary

    Sat, 29 Nov 2014

    Russell 2000 +0.07% . DJ Transports +1.14% , DJ Utilities +0.60 % . Pg M6, Europe: French big pharma Sanofi [ SAN .fr/ SNY ; flat YTD; fwd P/E 14.4; CEO search ongoing], Finnish telecom-network company Nokia [ NOK ; +15% YTD; sold

« Prev12345Next »
Content Partners